Formulation and characterization of hydrophilic drug diclofenac sodium-loaded solid lipid nanoparticles based on phospholipid complexes technology

Journal of Liposome Research

Volumn 24, Issue 1, 2014, Pages 17-26

  Liu, Dongfei ^a   Chen, Li ^a   Jiang, Sunmin ^a   Zhu, Shuning ^a   Qian, Yong ^a   Wang, Fengzhen ^a   Li, Rui ^a   Xu, Qunwei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Characterization; Core shell structure; Diclofenac sodium; Phospholipid complexes; Solid lipid nanoparticles

Indexed keywords

DICLOFENAC; PHOSPHOLIPID; SOLID LIPID NANOPARTICLE;

ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; HYDROPHILICITY; IN VITRO STUDY; INFRARED SPECTROSCOPY; IONIC STRENGTH; LIPOPHILICITY; NANOEMULSION; NANOENCAPSULATION; PARTICLE SIZE; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SURFACE CHARGE; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

DICLOFENAC; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPOSOMES; NANOPARTICLES; PHOSPHOLIPIDS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 84893214676     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2013.826241     Document Type: Article

References (47)

1. Almeida AJ, Runge S, Müller RH. (1997). Peptide-loaded solid lipid nanoparticles (SLN) influence of production parameters. Int J Pharm 149:255-65.
2. Almeida AJ, Souto E. (2007). Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59:478-90.
3. Attama AA, Muller-Goymann CC. (2007). Investigation of surfacemodified solid lipid nanocontainers formulated with a heterolipidtemplated homolipid. Int J Pharm 334:179-89.
4. Attama AA, Müller-Goymann CC. (2008). Effect of beeswax modification on the lipid matrix and solid lipid nanoparticle crystallinity. Colloids Surf A: physicochem Eng Aspects 315:189-95.
5. Avdeef A, Berger CM, Brownell C. (2000). pH-metric solubility. 2: correlation between the acid-base titration and the saturation shakeflask solubility-pH methods. Pharm Res 17:85-9.
6. Axelsson B. (1989). Liposomes as carriers for anti-inflammatory agents. Adv Drug Del Rev 3:391-404.
7. Baek SH, Kim B, Suh KD. (2008). Chitosan particle/multiwall carbon nanotube composites by electrostatic interactions. Colloids Surf A 316:292-6.
8. Baraf HSB, Fuentealba C, Greenwald M, et al. (2007). Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. J Rheumatol 34:408-20.
9. Bjerregaard S, Wulf-Andersen L, Stephens RW, et al. (2001). Sustained elevated plasma aprotinin concentration in mice following intraperitoneal injection of W/O emulsions incorporation approtinin. J Control Release 71:87-98.
10. Braem C, Blaschke T, Panek-Minkin G, et al. (2007). Interaction of drug molecules with carrier systems as studied by parelectric spectroscopy and electron spin resonance. J Control Release 119:128-35.
11. Brigger I, Dubernet C, Couvreur P. (2002). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631-51.
12. Chorny M, Fishbein I, Danenberg HD, Golomb G. (2002). Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release 83:389-400.
13. Cui F, Shi K, Zhang L, et al. (2006). Biodegradable nanoparticles loaded with insulin-phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release 114: 242-50.
14. Cui Z, Mumper RJ. (2002). Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. Int J Pharm 238: 229-39.
15. Gessner A, Olbrich C, Schröder W, et al. (2001). The role of plasma proteins in brain targeting: species dependent protein adsorption patterns on brain-specific lipiddrug conjugate (LDC) nanoparticles. Int J Pharm 214:87-91.
16. Gorner T, Gref R, Michenot D, et al. (1999). Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix. J Control Release 57:259-68.
17. Govender T, Stolnik S, Garnett MC, et al. (1999). PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 57:171-85.
18. Halter M, Antia M, Vogel V. (2005). Fibronectin conformational changes induced by absorption to liposomes. J Control Release 101:209-22.
19. Heiati H, Phillips NC, Tawashi R. (1996). Evidence for phospholipid bilayer formation in solid lipid nanoparticles formulated with phospholipid and triglyceride. Pharm Res 13:1406-10.
20. Hou Z, Wei H, Wang Q, et al. (2009). New method to prepare mitomycin C loaded PLA-nanoparticles with high drug entrapment efficiency. Nanoscale Res Lett 4:732-7.
21. Jiang SM, Ge YF, Bi XY, et al. (2010). Preparation methods of solid lipid nanoparticles (SLN) for hydrophilic peptides and proteins. Chin J Mod Appl Pharm 27:595-9.
22. Jumaa M, Muller BW. (2002). Parenteral emulsions stabilized with a mixture of phospholipids and PEG-660-12-hydroxy-stearate: evaluation of accelerated and long-term stability. Eur J Pharm Biopharm 54:207-12.
23. Kincl M, Vrecer F, Veber M. (2004). Characterization of factors affecting the release of low-solubility drug from prolonged release tablets. Anal Chim Acta 502:107-13.
24. Kong WH, Park K, Lee MY, et al. (2013). Cationic solid lipid nanoparticles derived from apolipoprotein-free LDLs for target specific systemic treatment of liver fibrosis. Biomaterials 34:542-51.
25. Liu D, Ge Y, Tang Y, et al. (2010). Solid lipid nanoparticles for transdermal delivery of diclofenac sodium: preparation, characterization and in vitro studies. J Microencapsul 27:726-34.
26. Liu DF, Jiang SM, Shen H, et al. (2011). Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method. J Nanopart Res 13:2375-86.
27. Liu J, Gong T, Wang C, et al. (2007). Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization. Int J Pharm 340:153-62.
28. Ma GL, Song CX. (2007). PCL/poloxamer 188 blend microsphere for paclitaxel delivery: influence of poloxamer 188 on morphology and drug release. J Appl Polym Sci 104:1895-9.
29. Mehnert W, Mader K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev 47:165-96.
30. Muller RH, Mader K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50:161-77.
31. Muller-Vahl H. (1983). Adverse reactions after intramuscular injections. Lancet 321:1050.
32. Peltonen L, Aitta J, Hyvonen S, et al. (2004). Improved entrapment efficiency of hydrophilic drug substance during nanoprecipitation of poly(l)lactide nanoparticles. AAPS PharmSciTech 5:E16.
33. Rahman Z, Zidan AS, Khan MA. (2010). Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm 76:127-37.
34. Schubert MA, Harms M, Muller-Goymann CC. (2006). Structural investigations on lipid nanoparticles containing high amounts of lecithin. Eur J Pharm Sci 27:226-36.
35. Schubert MA, Muller-Goymann CC. (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles - evaluation of the method and process parameters. Eur J Pharm Biopharm 55:125-31.
36. Shegokar R, Singh KK, Muller RH. (2011). Production &stability of stavudine solid lipid nanoparticles - from lab to industrial scale. Int J Pharm 416:461-70.
37. Shi K, Cui FD, Yu YW. (2006). Preparation and characterization of a novel insulin-phospholipid complex. Asian J Pharm Pharm Res 1: 168-74.
38. Shin SB, Cho HY, Kim DD, et al. (2010). Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur J Pharm Biopharm 74:164-71.
39. Shive MS, Anderson JM. (1997). Biodegradation and biocompatibility of PLA and PLGA microsphere. Adv Drug Deliv Rev 28:5-24.
40. Sinha VR, Trehan A. (2003). Biodegradable microspheres for protein delivery. J Control Release 90:261-80.
41. Souza SM, Oliveira ON, Scarpa Jr MV, Oliveira AG. (2004). Study of the diclofenac/phospholipid interactions with liposomes and monolayers. Colloids Surf B 36:13-17.
42. Stevens PJ, Lee RJ. (2003). Formulation kit for liposomal doxorubicin composed of lyophilized liposomes. Anticancer Res 23:439-42.
43. Takacsnovak K, Jozan M, Hermecz I, Szasz G. (1992). Lipophilicity of antibacterial fluoroquinolones. Int J Pharm 79:89-96.
44. Venkateswarlu V, Manjunath K. (2004). Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 95:627-38.
45. Yoo HS, Choi HK, Park TG. (2001). Protein-fatty acid complex for enhanced loading and stability within biodegradable nanoparticles. J Pharm Sci 90:194-201.
46. Zhang N, Ping QN, Huang GH, et al. (2006). Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 327:153-9.
47. zur Muhlen A, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 45:149-55.